Perioperative Management of Antiplatelet Therapy in Patients With History of Coronary Artery Disease Undergoing Surgery for Esophageal Cancer: A Single-center Experience

Conclusion: It is a reasonable approach to discontinue antiplatelet therapy for more than 7 days before surgery, especially in such a population of patients with esophageal cancer that require complex operations with high bleeding risk.

Source: In Vivo - February 25, 2019 Category: Research Authors: SCHIZAS, D., THEOCHARI, N. A., THEOCHARI, C. A., KOKKINIDIS, D. G., DOMI, V., MPAILI, E., JONNALAGADDA, A. K., KAPELOUZOU, A., BAKOPOULOS, A., LIAKAKOS, T. Tags: Clinical Studies Source Type: research